In This Article:
LYON, France, December 23, 2024--(BUSINESS WIRE)--Regulatory News:
Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity, today announced that its management team are scheduled to participate in the following upcoming investor conferences:
-
Annual BioPharma Obesity Innovation Forum, Sachs' Forum, January 11, 2025, San Francisco, United States
As part of this conference, which covers all aspects of bio-pharma obesity science, market trends and investment opportunities, Olivier Soula, CEO of Adocia, will participate in a panel discussion titled: "Obesity, Cardiovascular & Metabolic Diseases Platforms Panel", alongside distinguished leaders in the field (12:10pm - 1:00pm). -
JPM 2025 – 43rd Annual Healthcare Meeting, January 13-16, 2025, San Francisco, United States
Adocia will be present at events around the 2025 JP Morgan Healthcare Conference to engage with investors and healthcare industry leaders. -
ALLinvest Securities, BioMed Forum 2025, February 4, 2025, Paris, France
For the 10th edition of this forum dedicated to Biotech & Medtech, Olivier Soula will participate in a roundtable discussion focusing on obesity. -
Investor Access, April 1-2, 2025, Paris, France
This event brings together companies and investors for conferences and one-on-one meetings. -
LSX World Congress, April 28-30, 2025, London, United Kingdom
The event brings together CEOs and senior decision-makers from the world's most innovative biopharma, medtech and healthtech companies with investors, senior BD&L teams, R&D leaders and industry KOLs.
About Adocia
Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the field of metabolic diseases, primarily diabetes and obesity.
The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The BioChaperone® technology for the development of new generation insulins and products combining different hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell®, an immunoprotective biomaterial for cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel®, a long-acting drug delivery platform.
Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).